Document Detail

Effects of antihypertensive therapy on serum lipoproteins.
MedLine Citation:
PMID:  6138309     Owner:  NLM     Status:  MEDLINE    
Several drugs used for standard antihypertensive therapy may also interact with the lipoprotein metabolism. The following has been observed after 1 to 12 months of treatment. Various thiazide-type diuretics may significantly increase the potentially atherogenic serum low-density-lipoprotein cholesterol (LDL-C) and/or very-LDL-C-fractions, while the antiatherogenic high-density-lipoprotein cholesterol (HDL-C) is largely unchanged. Certain loop-diuretics also increase the LDL-C/HDL-C ratio and both types of diuretics elevated serum triglycerides (Tg) in some but not all studies. LDL-C was increased in diuretic-treated men and in chlorthalidone-treated postmenopausal women, but not in chlorthalidone-treated premenopausal women. The latter may be protected from this effect. Only two diuretics evaluated, namely indapamide and spironolactone, had no apparent influence on lipoproteins. Beta-blocker monotherapy may often increase Tg and slightly decrease HDL-C. The magnitude of these changes did not distinctly differ between highly cardioselective and nonselective beta-blockers, but it was less pronounced on beta-blockers than on those without intrinsic sympatholytic activity. Other sympatholytics such as reserpine, methyldopa, clonidine, debrisoquine, the alpha-beta-blocker labetalol, or the postsynaptic alpha-blocker, prazosin, did not affect or even slightly decrease Tg or total C, LDL-C, and very-LDL-C values. With combinations, a tendency for increased Tg and lower HDL-C was also apparent during thiazide-type diuretic-beta-blocker therapy. However, diuretic-induced increases in LDL-C were prevented or reversed by concomitant beta-blockade, but not by reserpine, methyldopa, or clonidine. Monotherapy with the potent direct vasodilator, carprazidil, improved blood pressure and significantly increased HDL-C. Prospective long-term studies are needed to clarify the course and the pathogenic and prognostic relevance of lipoprotein changes induced by certain diuretics or beta-blockers.
P Weidmann; A Gerber; R Mordasini
Related Documents :
24919719 - Nutritional interventions for preventing and treating pressure ulcers.
2861749 - Norepinephrine-induced beta 1-adrenergic peripheral vasodilation in conscious dogs.
6720529 - Intravenous labetalol in the management of severe hypertension and hypertensive emergen...
11040229 - Transforming growth factor beta in hypertensives with cardiorenal damage.
18223349 - Does beta blocker therapy affect the diagnostic accuracy of adenosine single-photon-emi...
6638039 - Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subj...
6652259 - Breathing pattern and efficiency of the respiratory muscles in healthy prematures and i...
7435599 - Effects of pressure on cerebrospinal fluid formation: nonsteady-state measurements in d...
6164109 - Aspiration pneumonia: treatment with osmotically active agents.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Hypertension     Volume:  5     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:    1983 Sep-Oct
Date Detail:
Created Date:  1983-12-17     Completed Date:  1983-12-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  III120-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Antihypertensive Agents / pharmacology*,  therapeutic use
Cholesterol / blood
Drug Therapy, Combination
Lipoproteins / blood*
Sodium Chloride Symporter Inhibitors / therapeutic use
Sympatholytics / therapeutic use
Time Factors
Triglycerides / blood
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Benzothiadiazines; 0/Diuretics; 0/Lipoproteins; 0/Sodium Chloride Symporter Inhibitors; 0/Sympatholytics; 0/Triglycerides; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The beta-adrenergic receptor in heart failure.
Next Document:  Adrenergic vasoconstriction as a cause of inadequate hypotensive response to beta-adrenergic blockad...